		TITY L OL	ILIU IL C	CCITOL	
¢	Approv	ved for Fili	ng: D.M. (Cheung	¢
	C	02-21-22	5:36 PM	©	

1	PHARMACY PRACTICE AMENDMENTS
2	2022 GENERAL SESSION
3	STATE OF UTAH
4	Chief Sponsor: Evan J. Vickers
5	House Sponsor:
6 7	LONG TITLE
8	General Description:
9	This bill amends the Pharmacy Practice Act $\hat{S} \rightarrow [and the Insurance Code] \leftarrow \hat{S}$.
10	Highlighted Provisions:
11	This bill:
12	Ŝ→ [
13	insured to disclose how a drug was paid for except to ensure compliance with state
14	or federal law;] ← Ŝ
15	 amends provisions related to the accepting back and redistributing of an unused
16	drug;
17	amends the definition of "interchangeable biological drug product";
18	 requires the Division of Occupational and Professional Licensing to designate by
19	rule therapeutically appropriate substitutes for insulin;
20	amends refill provisions for insulin;
21	amends provisions related to the dispensing of diabetes supplies;
22	 amends provisions related to the dispensing of prescription drugs by a hospital
23	pharmacy;
24	 authorizes the dispensing of a drug to treat a sexually transmitted disease by a
25	physician treating a patient at a state or local health department clinic; and
26	makes technical changes.
27	Money Appropriated in this Bill:



	None
Ot	her Special Clauses:
	None
Ut	ah Code Sections Affected:
AN	MENDS:
	58-17b-502, as last amended by Laws of Utah 2020, Chapter 25
	58-17b-503, as last amended by Laws of Utah 2016, Chapter 405
	58-17b-605.5, as last amended by Laws of Utah 2015, Chapter 266
	58-17b-608.2, as enacted by Laws of Utah 2020, Chapter 310
	58-17b-610.6, as enacted by Laws of Utah 2017, Chapter 44
	58-17b-610.8 , as enacted by Laws of Utah 2020, Chapter 372
	58-17b-803, as last amended by Laws of Utah 2015, Chapter 206
Ŝ	• [ENACTS:
	31A-22-657, Utah Code Annotated 1953] ←Ŝ
ъе	it enacted by the Legislature of the state of Utah:
	Ŝ→ [Section 1. Section 31A-22-657 is enacted to read:
	31A-22-657. Method of payment for drugs may not be requested.
_	Except to ensure compliance with state or federal law, neither an insurer nor a
_	armacy benefit manager as defined in Section 31A-46-102 may ask a pharmacy or an
	rollee of the insurer to disclose how a drug purchased from the pharmacy by the enrollee was
_	id for, including whether payment was received from one or more persons other than the rollee.
CIII	
	Section 2. Section 58-17b-502 is amended to read:
	Section 2. Section 58-17b-502 is amended to read: 58-17b-502 . Unprofessional conduct.
	Section 2. Section 58-17b-502 is amended to read: 58-17b-502 . Unprofessional conduct . (1) "Unprofessional conduct" includes:
90	Section 2. Section 58-17b-502 is amended to read: 58-17b-502. Unprofessional conduct. (1) "Unprofessional conduct" includes: (a) willfully deceiving or attempting to deceive the division, the board, or their agents
as	Section 2. Section 58-17b-502 is amended to read: 58-17b-502. Unprofessional conduct. (1) "Unprofessional conduct" includes: (a) willfully deceiving or attempting to deceive the division, the board, or their agents to any relevant matter regarding compliance under this chapter;
as	Section 2. Section 58-17b-502 is amended to read: 58-17b-502. Unprofessional conduct. (1) "Unprofessional conduct" includes: (a) willfully deceiving or attempting to deceive the division, the board, or their agents to any relevant matter regarding compliance under this chapter; (b) except as provided in Subsection (2):
	Section 2. Section 58-17b-502 is amended to read: 58-17b-502. Unprofessional conduct. (1) "Unprofessional conduct" includes: (a) willfully deceiving or attempting to deceive the division, the board, or their agents to any relevant matter regarding compliance under this chapter;

02-21-22 5:36 PM S.B. 236

59 (ii) paying, offering, receiving, or soliciting compensation in the form of a commission, 60 bonus, rebate, kickback, or split fee arrangement with practitioners or any other health care provider, for the purpose of obtaining referrals; 61 62 (c) misbranding or adulteration of any drug or device or the sale, distribution, or dispensing of any outdated, misbranded, or adulterated drug or device; 63 64 (d) engaging in the sale or purchase of drugs or devices that are samples or packages 65 bearing the inscription "sample" or "not for resale" or similar words or phrases; 66 (e) except as provided in Section 58-17b-503 \$→ [or Part 9, Charitable Prescription Drug Recycling Act $] \leftarrow \hat{S}$, accepting back and redistributing any unused drug, or a part of it, after it has **67** left the premises of [any] a pharmacy $\hat{S} \rightarrow [any]$, unless the drug is in a unit pack, as defined in Section 68 69 70 (f) an act in violation of this chapter committed by a person for any form of 71 compensation if the act is incidental to the person's professional activities, including the 72 activities of a pharmacist, pharmacy intern, or pharmacy technician; 73 (g) violating: 74 (i) the federal Controlled Substances Act, Title II, P.L. 91-513; 75 (ii) Title 58, Chapter 37, Utah Controlled Substances Act; or 76 (iii) rules or regulations adopted under either act; 77 (h) requiring or permitting pharmacy interns or technicians to engage in activities 78 outside the scope of practice for their respective license classifications, as defined in this 79 chapter and division rules made in collaboration with the board, or beyond their scope of 80 training and ability; 81 (i) administering: 82 (i) without appropriate training, as defined by rule; 83 (ii) without a physician's order, when one is required by law; and 84 (iii) in conflict with a practitioner's written guidelines or written protocol for administering; 85 86 (j) disclosing confidential patient information in violation of the provisions of the 87 Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat. 1936, as amended, or other applicable law; 88 89 (k) engaging in the practice of pharmacy without a licensed pharmacist designated as

151

121 an intermediate care facility for people with an intellectual disability that is licensed as a 122 nursing care facility or a small health care facility under Title 26, Chapter 21, Health Care 123 Facility Licensing and Inspection Act. 124 (b) "Nursing care facility" means the same as that term is defined in Section 26-21-2. 125 (c) "Unit pack" means a tamper-resistant nonreusable single-dose single-drug package 126 with identification that indicates the lot number and expiration date for the drug. 127 (2) A pharmacist may $\hat{S} \rightarrow$ accept and redistribute an unused drug, or part of it, after it has left the premises of the pharmacy $\leftarrow \hat{S}$: 127a (a) **\$→** [accept and redistribute an unused drug under] in accordance with ←**\$** Part 9. 128 Charitable Prescription Drug 128a 129 Recycling Act; $\hat{S} \rightarrow [or] \leftarrow \hat{S}$ 130 (b) \$→ [accept back and redistribute any unused drug, or a part of it, after it has left the 131 premises of the pharmacy | ←Ŝ if: 132 (i) the drug was prescribed to a patient in a nursing care facility, licensed intermediate 133 care facility for people with an intellectual disability, or state prison facility, county jail, or state 134 hospital; 135 (ii) the drug was stored under the supervision of a licensed health care provider 136 according to manufacturer recommendations; 137 (iii) the drug is in a unit pack or in the manufacturer's sealed container; 138 (iv) the drug was returned to the original dispensing pharmacy; (v) the drug was initially dispensed by a licensed pharmacist or licensed pharmacy 139 140 intern; and 141 (vi) accepting back and redistributing of the drug complies with federal Food and Drug 142 Administration and Drug Enforcement Administration regulations $\hat{S} \rightarrow [-]$; $\leftarrow \hat{S}$ 143 \hat{S} → $\frac{(3)}{(3)}$ A pharmacist may accept back and redistribute any unused drug, or a part of it, after 144 it has left the premises of the pharmacy (c) **←**Ŝ if: 144a $\hat{S} \rightarrow [(a)]$ (i) $\leftarrow \hat{S}$ the pharmacy has attempted to deliver the drug to a patient or a patient's 145 145a agent via 146 the United States Postal Service, a licensed common carrier, or supportive personnel; 147 $\hat{S} \rightarrow [\frac{b}{b}]$ (ii) $\leftarrow \hat{S}$ the drug is returned to the pharmacy by the same person or carrier that 147a attempted to 148 deliver the drug; and $\hat{S} \rightarrow [(c)]$ (iii) $\leftarrow \hat{S}$ in accordance with United States Food and Drug Administration 149 149a regulations and 150 rules established by the division, a pharmacist at the pharmacy determines that the drug has not

been adversely affected by the drug's attempted delivery and return.